{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:45:39Z","timestamp":1792806339086,"version":"4.5.0"},"reference-count":26,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Manchester Open Access Gateway","id":[{"id":"https:\/\/ror.org\/027m9bs27","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Objectives: to assess the safety profile of Gastrointestinal (GIT), renal, and pancreatic effects of GLP-1 and dual receptor agonists. Methods: Disproportionality analyses were performed on FDA Adverse Event Reporting System (FAERS) data following each drug\u2019s approval for weight management. Signals were identified using Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) with 95% confidence intervals (CIs). Results: Among GIT AEs, semaglutide (n = 12,321; 1.65%) showed the strongest signals (PRR 3.97, ROR 14.21), exceeding liraglutide (n = 5972, 0.45%, PRR 2.76, ROR 5.01) and tirzepatide (n = 4056, 3.48%, PRR 1.64, ROR 1.90). For renal and pancreatic outcomes, liraglutide demonstrated the highest overall signal (PRR 4.91, ROR 5.35), particularly for acute pancreatitis (PRR 18.9, ROR 19.4) and pancreatic carcinoma (PRR 18.6, ROR 19.5). Semaglutide showed stronger associations with diabetic ketoacidosis (DKA) (PRR 5.86, ROR 5.9) and acute kidney injury (AKI) (PRR 1.25, ROR 1.25). Tirzepatide demonstrated weaker or absent signals across most outcomes. Conclusions: This study revealed that semaglutide was most associated with GIT events, while liraglutide showed stronger renal and pancreatic signals. Novel associations with DKA and AKI were observed, warranting clinical vigilance. Findings should be cautiously interpreted given surveillance limitations, emphasising the need for large-scale real-world studies to confirm safety profiles.<\/jats:p>","DOI":"10.3390\/ph19010136","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:52:57Z","timestamp":1768319577000},"page":"136","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-0558","authenticated-orcid":false,"given":"Hala","family":"Shokr","sequence":"first","affiliation":[{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6377-6322","authenticated-orcid":false,"given":"Mohamed","family":"Mekkawy","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Alexandria Police Hospital, Alexandria 21511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-435X","authenticated-orcid":false,"given":"Ali","family":"Hindi","sequence":"additional","affiliation":[{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Liu, Q.K. (2024). Mechanisms of Action and Therapeutic Applications of GLP-1 and Dual GIP\/GLP-1 Receptor Agonists. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1431292"},{"key":"ref_2","unstructured":"(2025, May 11). The Evolving Story of Incretins (GIP and GLP-1) in Metabolic and Cardiovascular Disease: A Pathophysiological Update-Nauck-2021-Diabetes, Obesity and Metabolism-Wiley Online Library. Available online:  https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full\/10.1111\/dom.14496."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bulum, T. (2022). Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102586"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/oby.24002","article-title":"Efficacy and Safety of Tirzepatide, GLP-1 Receptor Agonists, and Other Weight Loss Drugs in Overweight and Obesity: A Network Meta-Analysis","volume":"32","author":"Pan","year":"2024","journal-title":"Obesity"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1001\/jama.2023.16620","article-title":"As Semaglutide\u2019s Popularity Soars, Rare but Serious Adverse Effects Are Emerging","volume":"330","author":"Ruder","year":"2023","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2042098620938595","DOI":"10.1177\/2042098620938595","article-title":"Post Marketing Surveillance of Suspected Adverse Drug Reactions through Spontaneous Reporting: Current Status, Challenges and the Future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_8","unstructured":"U.S. Food and Drug Administration (2024, January 10). FDA Adverse Event Reporting System (FAERS) Public Dashboard. FDA, Available online: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., and Zhang, Q. (2022). Gastrointestinal Adverse Events Associated with Semaglutide: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.996179"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DMSO.S348025","article-title":"Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study","volume":"15","author":"Zhou","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liu, L. (2024). A Real-World Data Analysis of Tirzepatide in the FDA Adverse Event Reporting System (FAERS) Database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1397029"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like Receptor-1 Agonists for Obesity: Weight Loss Outcomes, Tolerability, Side Effects, and Risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obes. Pillars"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100183","DOI":"10.1016\/j.glmedi.2025.100183","article-title":"Online Purchasing Options for GLP-1 Agonists: Accessibility, Marketing Practices, and Consumer Safety Concerns","volume":"5","author":"Basch","year":"2025","journal-title":"J. Med. Surg. Public Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management","volume":"70","author":"Singh","year":"2022","journal-title":"J. Investig. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2457232","DOI":"10.1001\/jamanetworkopen.2024.57232","article-title":"Longitudinal Analysis of Obesity Drug Use and Public Awareness","volume":"8","author":"Berning","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Liu, L., Chen, J., Wang, L., Chen, C., and Chen, L. (2022). Association between Different GLP-1 Receptor Agonists and Gastrointestinal Adverse Reactions: A Real-World Disproportionality Study Based on FDA Adverse Event Reporting System Database. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1043789"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13098-023-01198-4","article-title":"Efficacy and Safety of Tirzepatide, Dual GLP-1\/GIP Receptor Agonists, in the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"15","author":"Zhou","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","article-title":"GLP-1 Receptor Agonists\u2019 Impact on Cardio-Renal Outcomes and Mortality in T2D with Acute Kidney Disease","volume":"15","author":"Pan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","article-title":"Glucagon-like Peptide-1 Receptor Agonists and Pancreatitis: A Meta-Analysis of Randomized Clinical Trials","volume":"103","author":"Monami","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety Issues with Glucagon-like Peptide-1 Receptor Agonists (Pancreatitis, Pancreatic Cancer and Cholelithiasis): Data from Randomized Controlled Trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e70113","DOI":"10.1002\/edm2.70113","article-title":"Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"8","author":"Wen","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Guo, H., Guo, Q., Li, Z., and Wang, Z. (2024). Association between Different GLP-1 Receptor Agonists and Acute Pancreatitis: Case Series and Real-World Pharmacovigilance Analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1461398"},{"key":"ref_23","unstructured":"Annual General Meeting (AGM) (2025, July 23). GLP-1 RAs Associated with Increased Risk of Gallstones, Reflux, Meta-Analysis Finds. Available online: https:\/\/gastroenterology.acponline.org\/archives\/2025\/06\/27\/1.htm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","article-title":"Acute Renal Effects of the GLP-1 Receptor Agonist Exenatide in Overweight Type 2 Diabetes Patients: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.xkme.2020.10.008","article-title":"Acute Kidney Injury Associated with Semaglutide","volume":"3","author":"Leehey","year":"2021","journal-title":"Kidney Med."},{"key":"ref_26","unstructured":"(2025, July 17). FAERS Quarterly Data Extract Files, Available online: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/1\/136\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:58:12Z","timestamp":1768319892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/1\/136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ph19010136"],"URL":"https:\/\/doi.org\/10.3390\/ph19010136","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]}}}